Related references
Note: Only part of the references are listed.Efficacy and safety of oral solithromycin versus oral moxifloxacin for treatment of community-acquired bacterial pneumonia: a global, double-blind, multicentre, randomised, active-controlled, non-inferiority trial (SOLITAIRE-ORAL)
Carlos M. Barrera et al.
LANCET INFECTIOUS DISEASES (2016)
Mortality among severe community-acquired pneumonia patients depends on combinations of 2007 IDSA/ATS minor criteria
Hai-yan Li et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2015)
Empirical Therapy of Community-Acquired Pneumonia Advancing Evidence or Just More Doubt?
Lionel A. Mandell et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Azithromycin drives alternative macrophage activation and improves recovery and tissue sparing in contusion spinal cord injury
Bei Zhang et al.
JOURNAL OF NEUROINFLAMMATION (2015)
Community-Acquired Pneumonia in Older Adults
Thomas R. Breen et al.
CURRENT GERIATRICS REPORTS (2015)
Fitness cost associated with resistance to fluoroquinolones is diverse across clones of Klebsiella pneumoniae and may select for CTX-M-15 type extended-spectrum β-lactamase
A. Toth et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2014)
Oral fluoroquinolone use and risk of peripheral neuropathy A pharmacoepidemiologic study
Mahyar Etminan et al.
NEUROLOGY (2014)
Update on antimicrobial susceptibility trends among Streptococcus pneumoniae in the United States: report of ceftaroline activity from the SENTRY Antimicrobial Surveillance Program (1998-2011)
Ronald N. Jones et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2013)
Risks associated with the therapeutic use of fluoroquinolones
Ralf Stahlmann et al.
EXPERT OPINION ON DRUG SAFETY (2013)
Does Empiric Therapy for Atypical Pathogens Improve Outcomes for Patients with CAP?
Thomas M. File et al.
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA (2013)
Clinically Relevant Mutant DNA Gyrase Alters Supercoiling, Changes the Transcriptome, and Confers Multidrug Resistance
Mark A. Webber et al.
MBIO (2013)
A Novel Macrolide Solithromycin Exerts Superior Anti-inflammatory Effect via NF-κB Inhibition
Yoshiki Kobayashi et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2013)
Selective Protein Synthesis by Ribosomes with a Drug-Obstructed Exit Tunnel
Krishna Kannan et al.
CELL (2012)
Predictors of In-Hospital vs Postdischarge Mortality in Pneumonia
Mark L. Metersky et al.
CHEST (2012)
SOLITHROMYCIN Macrolide Antibiotic
P. Fernandes et al.
DRUGS OF THE FUTURE (2011)
In Vitro Activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with Defined Macrolide Resistance Mechanisms
Pamela McGhee et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Binding and Action of CEM-101, a New Fluoroketolide Antibiotic That Inhibits Protein Synthesis
Beatriz Llano-Sotelo et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Integrated Analysis of FOCUS 1 and FOCUS 2: Randomized, Doubled-Blinded, Multicenter Phase 3 Trials of the Efficacy and Safety of Ceftaroline Fosamil versus Ceftriaxone in Patients with Community-Acquired Pneumonia
Thomas M. File et al.
CLINICAL INFECTIOUS DISEASES (2010)
Antimicrobial characterisation of CEM-101 activity against respiratory tract pathogens, including multidrug-resistant pneumococcal serogroup 19A isolates
David J. Farrell et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2010)
Comparative In Vitro Susceptibilities of Human Mycoplasmas and Ureaplasmas to a New Investigational Ketolide, CEM-101
Ken B. Waites et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia
M. I. Restrepo et al.
EUROPEAN RESPIRATORY JOURNAL (2009)
Long-Term Morbidity and Mortality After Hospitalization With Community-Acquired Pneumonia A Population-Based Cohort Study
Jennie Johnstone et al.
MEDICINE (2008)
Antibiotics for bacteremic pneumonia - Improved outcomes with macrolides but not fluoroquinolones
Mark L. Meterky et al.
CHEST (2007)
A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality
VG Loo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea:: A cohort study during an epidemic in Quebec
J Pépin et al.
CLINICAL INFECTIOUS DISEASES (2005)
Share Paper
